Please login to the form below

renal disease

This page shows the latest renal disease news and features for those working in and with pharma, biotech and healthcare.

Price matters

And when patients cannot pay for their kidney transplants, or the waiting list for end-stage renal disease patients is so long that they die waiting for a transplant, they have

Latest news

Amgen's chronic kidney disease drug Parsabiv cleared in US

Amgen's chronic kidney disease drug Parsabiv cleared in US. Sensipar follow-up is the first therapy to be approved for treatment of sHPT in 12 years. ... However, some have warned that there could be pushback resulting from tighter reimbursement rules
Assisting adherence

At the same time, kidney transplantation is the treatment of choice for a growing number of patients with end-stage renal disease.
SMC approves Opdivo combo as first-line skin cancer treatment

Amicus Therapeutics' Galafold (migalastat) has also received the go-ahead, and has been sanctioned by the SMC for the treatment of adults with Fabry disease, an incurable inherited genetic disorder. ... greater enzyme activity after evidence of renal,
NICE backs expanded use of Brilique in final guidance

Patients who are at high risk of repeat cardiovascular events are often older, with evidence of multi-vessel coronary artery disease, chronic non-end-stage renal dysfunction or diabetes mellitus. ... In order to achieve this the firm is working on new
Keryx Biopharmaceuticals' Fexeric approved in EU

Keryx Biopharmaceuticals' Fexeric approved in EU. New treatment option for chronic kidney disease. ... the reach of ferric citrate to treat patients with renal disease.”. “

More from news
Approximately 1 fully matching, plus 54 partially matching documents found.

Latest Intelligence

Deal Watch February 2017

Ionis has recently received a $75m milestone payment from Bayer having successfully completed a phase II study on IONIS-FXIRx in patients with end-stage renal disease on haemodialysis. ... Royalty monetisation. 150. BIAL/ Neurocrine Biosciences. ONGENTYS
Deal Watch November 2015

386. AstraZeneca. Perrigo. Acquisition - asset. Entocort (budesonide) marketed for mild to moderate Crohn's disease. ... Option to license. 175. Idera Pharmaceuticals. GlaxoSmithKline. Licence, collaboration. Antisence platform for selected targets in
The rising prevalence of diabetes in Europe

Stroke: Risk is up to four times higher with diabetes. Cardiovascular disease: Risk is up to four times higher with diabetes. ... Diabetic nephropathy: This is the leading cause of end-stage renal disease.
Deal Watch table for February 2014

Company acquisition. Rare disease company with marketed products in US (Chenodal to treat CTX. ... 12. 1. Co-promotion rights in US. 2. Endstage renal disease. 3.
Deal Watch table for November 2013

548. Cytori/Lorem. Vascular. Licence. Cell therapy for CVS, diabetes, and renal disease. ... 152. Calidus / Amicus. Acquisition. Purchase of Callidus' late-stage enzyme replacement therapy for Pompe disease.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest from PMHub

Digital health: Breaking barriers in Health by Debashis Bhattacharya and Kamlesh Sheth

Unsurprisingly, certain chronic conditions— like rheumatologic conditions, renal disease, diabetes, and AIDS— are associated with persistent high, long-term healthcare spending.
PAN and DJM win prestigious Global Award

Mimpara is approved for the treatment of secondary hyperparathyroidism (SHPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy, and it was for this indication that the

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Home based, Principal Medical Writer, Medical Communications: Excellent package

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Business Unit Head, Medical Communications, London: Excellent package

Home based, Senior Medical Writer, Medical Communications: Excellent package

Client Services Director - Med Comms: Great salary and bebefits

Home based, Chief Medical Writer, Medical Communications: Excellent package

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Editorial Director – Medical Education (MedComms): Neg

Healthcare PR Director: £100, 000 – £120, 000 benefits

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Home based, Editorial Team Leader, Medical Communications: Excellent package

Account Manager: £40, 000 - £45, 000 benefits

Client Services Director – Healthcare Advertising - London: Neg

Delivery Manager/ Head of Delivery – Executive Search: Neg

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Subscribe to our email news alerts

PMHub

Add my company

M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....